Shape Therapeutics Unveils AAVid™ Capsid Discovery Platform and Identification of Novel Tissue-Specific AAV Variants, Solving a Fundamental Delivery Challenge in Gene Therapy


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Shape Therapeutics Unveils AAVid™ Capsid Discovery Platform and Identification of Novel Tissue-Specific AAV Variants, Solving a Fundamental Delivery Challenge in Gene Therapy
Shape Therapeutics, announces today the unveiling of the AAVidTM capsid discovery platform and results from its first AAV5 variant library in a non-human primate selection campaign.

Shape Therapeutics, Inc. a next-generation gene therapy company with an industry-leading RNA targeting technology platform, announces today the unveiling of the AAVidTM capsid discovery platform and results from its first AAV5 variant library in a non-human primate selection campaign.

The AAVidTM capsid discovery platform uses non-random mutational fitness to create massive capsid libraries of billions of unique AAV variants for direct-to-NHP in vivo biological selection. By combining cutting-edge DNA synthesis, advanced synthetic biology, next-generation sequence barcoding, and machine learning algorithms, ShapeTX generates industry-leading library size and diversity to enable the development of best-in-class human therapeutics.

 

“Wildtype first-generation AAVs are enabling the recent advances in gene therapy, but they have been plagued by toxicities in the clinic due in part to a lack of tissue specificity, resulting in the need for high doses. Our AAVidTM platform solves the issue by creating novel capsid variants with specific tissue-tropism,” said Francois Vigneault Ph.D., President, and CEO at ShapeTX. “We’ve stayed quiet for the past three years while developing a superior AAV platform technology and are excited to announce that we have best-in-class AAV variants in hand. Today, we are announcing our novel liver-tropic AAV5 variants – stay tuned for more to come.”

 

David J. Huss, Ph.D., Vice President and Head of Research added, “The vast structural space for exploration at the AAV capsid/target cell interface necessitates enormous library size and diversity, which until now, has only been probed with capsid library sizes in the tens of thousands to millions. At ShapeTX, we set out to create a superior AAV capsid discovery platform with library sizes in the billions of unique variants, thereby maximizing the opportunity for novel virus/target cell interactions.” Dr. Huss presented the details of the platform at the 2nd RNA Editing Summit on Dec. 2, 2020.

 

About Shape Therapeutics, Inc

Shape Therapeutics is a biotechnology company developing next-generation RNA-targeted therapies to treat the world’s most challenging diseases. The ShapeTX technology platform includes RNAskip™, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfixTM, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVidTM, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs. The power of the ShapeTX platforms resides in redirecting the cellular machinery already present in our cells, thereby bypassing the risks of immunogenicity and DNA damage seen with other contemporary editing technologies. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing life-long cures to patients. Shape Life!

Tags : #ShapeTherapeutics #GeneTherapyCompany #AAVidCapsid #AAVid #AAV5 #DavidJHuss #RNAfix #RNAskip

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

India on the Boil: Unmasking the Heatwave Crisis and the Cooling Power of Traditional WisdomApril 25, 2025
The Creamy Culprit: How Raw Egg Mayonnaise Became a Public Health Hazard in IndiaApril 25, 2025
The Invisible Childhood Enemy Behind Young Adult Colon CancerApril 25, 2025
TERN Group charts the future of ethical nurse migration with scalable impact.April 25, 2025
6 Gut-Friendly Foods That Soothe an Irritated StomachApril 25, 2025
Top 5 IVF Centres in India – Best IVF Clinics for Fertility TreatmentApril 25, 2025
HighTide Therapeutics to Showcase New Analyses of Phase 2 MASH/T2DM Studies of Berberine Ursodeoxycholate (HTD1801) and Pre-Clinical Results of Rimtoregtide (HTD4010) in Presentations at EASL Congress 2025April 25, 2025
World Malaria Day: Why India Must Not Let Its Guard DownApril 25, 2025
Murder in the Name of God: Kashmir and the Collapse of HumanityApril 24, 2025
6 Early Warning Signs of Malaria You Shouldn’t IgnoreApril 24, 2025
World Meningitis Day: A Loud Alarm for a Quiet KillerApril 24, 2025
Amid Documented Progress, India’s Malaria-Free Dream Faces Ground Realities.April 24, 2025
Medanta Surgeons Remove Rare Tumour, Rebuild Face of Iraqi Toddler in 14-Hour Surgery.April 24, 2025
Burnett Homeopathy Hosts Historic World Homeopathy Summit 3 During World Homeopathy Week in Germany April 24, 2025
Mind Over Meltdown: The Underrated Skill Saving Relationships and SanityApril 23, 2025
Moscow Accelerates AI Testing in Healthcare with New Diagnostic MethodApril 23, 2025
The Weight Loss Drug That Could Weigh Down Your Mind: A Closer Look at Ozempic’s Hidden CostApril 23, 2025
The Chaos That Makes You Human: How Disorder in the Brain Creates Order in ThoughtApril 23, 2025
Benefiting 7,000 Children Across 30 Schools with CSR InitiativesApril 23, 2025
MGM Healthcare Performs Life-Saving Surgery on 6-Year-Old Boy with Severe Heart BlockageApril 23, 2025